Medication-Related Osteonecrosis of the Jaw (MRONJ), first identified in 2002, adversely affects patients’ quality of life, producing significant morbidity. Cases continue to increase. It may affect patients undergoing intravenous cancer-related therapy or, more rarely, patients treated with oral or IV bisphosphonates for osteoporosis. This webinar will review current definitions of MRONJ, strategies for diagnosing, staging, and managing it, and the relevance to treatment planning dental implant therapy.

After completion of the program, participants should be able to:

- Identify the medications associated with MRONJ, including the new antiresorptive and antiangiogenic therapies.
- Identify the risks of developing MRONJ.
- Diagnose MRONJ in patients with a history of exposure to this class of medications.
- Better understand MRONJ prevention measures and management strategies.

Federico Grande, DDS, MD
Dr. Grande received his Bachelor’s degree in Biology from the University of Miami in Miami, FL, his dental degree from Northwestern University Dental School, and his doctorate degree from the University of Miami School of Medicine. He completed his residency program in Oral and Maxillofacial Surgery at the University of Miami/Jackson Memorial Hospital in Miami, FL. Dr. Grande is a fellow of the American Association of Oral & Maxillofacial Surgeons, as well as a Fellow of American Dental Society of Anesthesiology. Dr. Grande maintains a private practice, with an emphasis on full scope Oral & Maxillofacial Surgery in Stuart, FL.

DATE/TIME: On Demand-Viewing
CONTINUING EDUCATION: 1 Credit
FEE: Complimentary*

TO REGISTER FOR THIS PROGRAM:
• Go to zimmerbiometdental.com/on-demand

For additional information regarding this program, please contact the Zimmer Biomet Dental Education Department at: events@zimmerbiomet.com.